
Tying Alcohol to Poor Sleep to Discourage Drinking
This transcript has been edited for clarity.
Welcome to Impact Factor , your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson from the Yale School of Medicine.
You may not have realized it yet, but we are full-on in the era of biofeedback. I remember a few years ago when my smartwatch started reporting on my heart rate variability during sleep.
To be honest, I didn't even know what this metric really meant. But I did notice something fairly early on. On nights when I drank alcohol, my heart rate variability went down.
Human brains are really good at linking pieces of data like that, and I kept an eye on it, with additional nights of drinking or not drinking and more reports of heart rate variability only strengthening the association. This is not unique to me, of course — multiple studies have demonstrated the link between alcohol and decreased parasympathetic tone, which is the thing that causes the decrease in heart rate variability.
But for me, it was the first time I really saw a physiologic consequence of alcohol intake right before my eyes. Sure, everyone has had a hangover, but this phenomenon was there even if I had only had a glass of wine and felt fine waking up.
And it had an effect on me. There was something about seeing that number — maybe it's my competitive nature — that made me want to improve it. I guess the behavioral scientists might call this gamification, but whatever you want to call it, the net-net was that I started drinking less.
This is the power of biofeedback: You get information about your physiologic state to make the effects of your actions more real. And, with wearable devices now ubiquitous, it seems like the perfect time to test whether anecdotes like mine hold up in the real world. We got a randomized trial to answer that question just last week.
I'm thinking about my wearable device this week because of this study, appearing in JAMA Network Open, examining the complex relationship between alcohol use and sleep in a population of 120 young adults aged 18-25. Full disclosure: This was a study out of Yale, but I was not involved in any way.
The researchers, led by Lisa Fucito, wanted to test whether biofeedback — in this case, making explicit the link between alcohol intake and sleep quality — could modify alcohol use behavior.
Let's digress for a minute to talk about alcohol and sleep. There is something of a two-way street here. In general, alcohol use decreases the quality of sleep; you wake up more, sleep less, and have less restful sleep overall. But bad sleep can also influence alcohol intake. After a poor night's sleep you have less self-control, less discernment — you might make worse decisions — and none of that is conducive to saying 'no thanks I've had enough' when someone is offering you a shot at the local watering hole.
To track alcohol intake and sleep quality, the researchers strapped two wearable devices on to each participant. The first was a sleep actigraphy monitor — basically a device that can tell how much you sleep, how deeply, the quality, and so on. The second device was an alcohol monitor. You may have heard of this 'SCRAM' technology that police sometimes use to ensure someone isn't drinking. It samples the alcohol we excrete in our sweat.
While every participant wore these devices for 2 weeks, only half of them were given the information the devices provided. The rest were divided into two control groups. One group was given some web-based information about the importance of sleep, and the other group received the same web-based information but were also asked to keep a diary of their drinking behavior and subjective sleep quality.
The intervention group is the interesting one here, of course. At the end of week 1 and 2, a trained coach reviewed each participant's data with them. They showed them their blood alcohol content, their sleep data, and crunched this all into clear numbers like the ones you see here.
This participant can see that on their non-drinking nights, their sleep quality is better than on their drinking nights.
So, with my personal anecdotal data as a guide, this intervention must clearly have led to decreased drinking, right? Well, sort of. But not really.
This is the number of drinks per week at each of four time points. Remember, the intervention only lasted for the first 2 weeks. The primary outcome was the number of drinks at week 12.
You can see quite clearly an interesting effect; all three groups drank less over time. The intervention with the cool biofeedback, the people who just kept a drinking diary, even the people who got the web-based sleep information program. Everyone.
This is actually a classic finding in studies like this known as the Hawthorne effect. It occurs when individuals change their behavior because they are aware they are being studied. You see it in all kinds of behavioral intervention studies. If they know you're watching, people are more likely to wash their hands, leave a tip, hold a door for a stranger. It's powerful. But it's also short lived. When the study is over, people tend to go back to their old behavior.
Unfortunately, this makes it tough to assess the intervention itself. Perhaps it really would work in the real world, when big brother isn't watching, but we can't tell in the world of a clinical trial because all the guinea pigs know they are guinea pigs.
That said, some of the secondary outcomes were positive. The intervention group had lower rates of sleep impairment and sleep disturbance. That's an odd finding since we know this improvement couldn't have been mediated by less alcohol drinking. Maybe feedback about your sleep quality makes you change other things independent of alcohol? Maybe you're just a bit more mindful about the whole thing?
We should also remember that these were all 18 to 25-year-olds. I don't want to sound like an old fogey here, but I will say that I think I was well into my 30s before I took a hard look at some of my less than healthy behaviors and started to make real changes. There are a lot of other pressures on these young adults. Cutting back on drinking may just not be the most important thing to them at this point in their life.
So, no, I'm not ready to give up on biofeedback as an agent of behavior change. I still think this area is promising, but we may need to come up with some more clever ways to study it. For now, I'm keeping an eye on my heart rate variability at night; I am a data guy after all. It may not work for everyone, but it works for me, and if it works for you, then that's good enough.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


New York Post
10 hours ago
- New York Post
Unregulated chemical 13,000 times sweeter than sugar is used in most e-cigarettes: study
A little-known artificial sweetener that's up to 13,000 times sweeter than sugar is now used in most popular flavored e-cigarettes — even though it is not listed on labels and is only FDA-approved for food, a new study found. Neotame was detected in 57 of 73 flavored vaping products often marketed to kids and teens and had an average content nearly five times higher than in a mint candy, a study conducted by researchers from Yale School of Medicine and Duke University found. Little is known about the health effects of inhaling the potent, no-calorie alternative, which was created by NutraSweet and is also known as Newtame, and current regulations do not limit its use, according to the June 2 study published in the Journal of the American Medical Association. 3 Researchers at Yale detected the sweetener in a majority of flavored vaping products on the market. The researchers set out to prove, mainly to regulators and clinicians, how commonly the chemical, which is also up to 65 times sweeter than aspartame, is being used in newer products, they said. All popular disposable e-cigs introduced after 2021 that haven't yet received U.S. Food and Drug Administration marketing authorization — 27 devices across 11 different brands — contained neotame, according to the study. Among them were vapes from brands like Breeze Smoke, Elf Bar and Vapetasia, which offer flavors like Strawberry Apple, Killer Kustard and Blue Razz Ice. Products from three brands — Vuse and NJOY, which are FDA-approved, and JUUL, which is awaiting approval — that were introduced before 2021 do not contain it, the study found. The substance was likely chosen for its heat stability compared to other sweeteners, but its behavior when heated and vaporized in e-cigarettes is unknown, the scientists wrote in their findings. 3 Flavored e-cigarettes, often marketed to kids and teenagers, are rife with the artificial sweetener neotame. Vapetasia 'There are two specific concerns about the finding: How does it affect the potential for addiction to the product, and what are the product's adverse health effects when inhaled?' said Hanno Erythropel, the paper's lead author. 'Eating versus inhaling something is very different,' Erythropel, a Yale researcher, added. 'There are many examples in which chemicals are safe for eating but not for inhalation.' Neotame is approved by the FDA for use in food, but not in vaping products, according to the researchers. When eaten in foods like cakes, soft drinks and chewing gum, neotame can seriously damage gut health, a study published last year in the medical journal Frontiers found. 3 Neotame is an artificial sweetener similar to aspartame. luchschenF – 'The respiratory and systemic health effects of neotame and its potential decomposition products during heating in an e-cigarette are unknown,' the scientists said. Alarmingly, most of the 'funky' flavors used in e-cigarettes have not been evaluated for use in products other than food, Erythropel added. The team hopes its findings pave the wave for further studies on neotame toxicity and exposure once it is heated and inhaled, and how users rate the appeal of e-cigarettes that contain it.
Yahoo
a day ago
- Yahoo
Everything you need to know about headaches for Headache Awareness Month
NEW HAVEN, Conn. (WTNH) — June is Headache Awareness Month. In today's health headlines, we discuss what to know about the most common headache types, how to tell them apart, and tips for preventing a tension headache. Dr. Vanessa Cooper, Yale Medicine neurologist specializing in headaches and assistant professor at Yale School of Medicine, joined Good Morning Connecticut at 9 a.m. to discuss. Watch the video above to learn more. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
3 days ago
- Yahoo
Clearmind Medicine Announces Enrollment of First Patient in Phase I/IIa Clinical Trial for Alcohol Use Disorder Treatment
CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ('Clearmind' or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the enrollment of the first patient in its Phase I/IIa clinical trial for CMND-100, a proprietary MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD). The first patient was enrolled at Yale School of Medicine's Department of Psychiatry, marking a significant milestone in the trial. The trial is evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy assessments to explore its potential in reducing alcohol cravings and consumption. This first-in-human study represents a pivotal step toward developing a groundbreaking treatment for individuals struggling with AUD. Eligible subjects for the clinical trial, among others, are individuals aged 18 to 60. Participants may be either non-treatment-seeking individuals who report heavy binge drinking (defined as at least five standard drinks in a day for men or at least four for women) on at least five days in the past month prior to screening, or treatment-seeking individuals diagnosed with Alcohol Use Disorder (AUD) per DSM-5 criteria, who report at least four binge drinking days in the month prior to screening. All subjects must express a desire to reduce or stop drinking. For more information: 'The enrollment of our first patient at Yale School of Medicine marks a pivotal milestone in the development of CMND-100,' said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. 'This advancement brings us one step closer to offering an innovative solution for those affected by AUD, a condition with significant unmet medical needs. The substance use disorder treatment market in the U.S. alone was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029. Moreover, there are hundreds of millions of individuals around the globe afflicted by AUD. However, the market has been constrained due to the limited effectiveness and adverse side effects of current treatment options. We are executing on our development strategy and are optimistic about the potential of our MEAI-based therapy to offer a safe, effective solution that can transform lives.' The Phase I/IIa clinical trial is being conducted at multiple sites, including Yale School of Medicine and Johns Hopkins University School of Medicine, while the Company is valuating additional clinical sites. Clearmind remains committed to advancing its robust intellectual property portfolio and pioneering psychedelic-derived therapeutics to address global health challenges. About Clearmind Medicine Inc. Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The Company's intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol 'CWY0.' For further information visit: or contact: Investor Relations invest@ Telephone: (604) 260-1566 US: CMND@ General Inquiries Info@ Forward-Looking Statements: This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses conducting its Phase I/IIa clinical trial, developing a treatment for individuals struggling with AUD, the size of the substance use disorder treatment market, executing its development strategy, valuating additional clinical sites, and that it remains committed to advancing its robust intellectual property portfolio and pioneering psychedelic-derived therapeutics to address global health challenges. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the Securities and Exchange Commission ('SEC'), including, but not limited to, the risks detailed in the Company's annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data